Vinpocetine 10 mg

Vinpocetine 10 mg

Life Extension4.6 (1,612 ratings)
Format:Tablet Quantity: 100 Tablet(s) · 100 servings
Goals
$14.00 $0.14 per serving

Product analysis

59 out of 100

Vinpocetine 10 mg offers a simple supplement aimed at brain and focus support. Its proposed role in brain blood flow does not establish dependable cognitive benefits for healthy adults.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality24

The calcium source is named, while the vinpocetine form is unspecified. There is too little information to judge their quality closely.

Ingredient Transparency81

Both listed amounts are disclosed. The calcium form is identified, while the vinpocetine form is not.

Value For Money72

The cost relative to the vinpocetine amount offers good value. There is not enough value information for the calcium contribution.

Customer Satisfaction82

Customer feedback is very positive across more than a thousand ratings. The review base provides a useful picture of satisfaction.

Product Focus56

The intended uses involve brain function and everyday attention. Dependable benefit in healthy adults remains unestablished, and the serving amount alone does not resolve that uncertainty.

Format
Tablet
Container
100 Tablet(s)
Per serving
$0.14
Customer rating
4.6 · 1,612 ratings
Report analysis

Goals

Brain Health
Impact
High effect
C+ Ingredient FitD- PathwaysC+ EvidenceA+ Formulation Logic

Vinpocetine is included for its connection to brain blood flow and energy processes. The supplied research context does not establish dependable cognitive benefits for healthy adults. The 10 mg serving receives partial amount recognition in the saved findings; the optional repeated-use directions are not treated as a larger serving.

How this product is rated for Brain Health

Ingredient fit68

The ingredient selection connects to brain health, with serving amounts and the formula’s wider purpose shaping how focused that connection is.
Goal fit
The formula includes brain-relevant ingredients alongside a broader mix of ingredients and intended uses.
Dose adequacy
The recognized amounts provide partial overall coverage of the saved references, rather than establishing a proven effective cognitive dose.

Pathways41

The strongest saved connection is cerebral energy metabolism; this describes the ingredient grouping rather than a demonstrated brain-health outcome. One area reaches the saved coverage threshold, leaving the connection concentrated rather than broad.
Depth
The strongest saved connection is cerebral energy metabolism; this describes the ingredient grouping rather than a demonstrated brain-health outcome.
Breadth
One area reaches the saved coverage threshold, leaving the connection concentrated rather than broad.

Evidence68

The saved evidence findings recognize ingredients and preparations, while the supplied scientific context limits expectations for general cognitive improvement.
Evidence strength
Vinpocetine leads the saved evidence finding, while the supplied research context limits claims of broad cognitive improvement.
Studied preparation
The saved findings recognize the included preparations; this does not establish equivalence where the supplied scientific context distinguishes extracts or populations.

Formulation logic100

The saved findings identify no missing required partners or configured conflicts. Amount recognition does not itself establish an effective cognitive outcome.
Partner coverage
The recognized ingredients have no missing required partner in the saved findings; this does not establish an added benefit from combining them.
Conflicts
No configured conflict was identified. The caffeine-specific checks do not apply because no qualifying caffeine amount is established.
Effective doses
All ingredients included in this finding meet its minimum amount threshold, which is a comparison reference rather than a proven cognitive dose.
Study evidence
Productivity Boost
Impact
Lower effect
C Ingredient FitF PathwaysF EvidenceA+ Formulation Logic
Vinpocetine · 10 mg
Study evidence
Mental Focus
Impact
Moderate effect
C Ingredient FitF PathwaysC+ EvidenceA+ Formulation Logic

Vinpocetine has a proposed connection to cerebral energy supply and blood flow, but the supplied evidence does not establish reliable improvement in everyday attention in healthy adults. The 10 mg amount receives only partial support in the saved exposure comparison.

How this product is rated for Mental Focus

Ingredient fit62

The saved assessment identifies 1 relevant ingredients and 1 other active ingredients; the formula serves 3 goals. The saved amount assessment is limited overall, with unknown amounts contributing no support.
Goal fit
The saved assessment identifies 1 relevant ingredients and 1 other active ingredients; the formula serves 3 goals.
Dose adequacy
The saved amount assessment is limited overall, with unknown amounts contributing no support.

Pathways13

Cerebral energy supply is the strongest represented mechanism, with partial coverage in the saved findings. 0 of the three mechanism targets meets the saved coverage threshold.
Depth
Cerebral energy supply is the strongest represented mechanism, with partial coverage in the saved findings.
Breadth
0 of the three mechanism targets meets the saved coverage threshold.

Evidence65

Vinpocetine leads the saved evidence comparison among ingredients meeting the amount threshold. This comparison does not imply uniform focus improvement. The qualifying ingredients match the preparations recognized by the saved assessment.
Evidence strength
Vinpocetine leads the saved evidence comparison among ingredients meeting the amount threshold. This comparison does not imply uniform focus improvement.
Studied preparation
The qualifying ingredients match the preparations recognized by the saved assessment.

Formulation logic100

The assessed ingredients work alone or have their required partner. No configured conflict was identified. 1 of 1 assessed ingredients meet the saved minimum amount threshold.
Partner coverage
The assessed ingredients work alone or have their required partner.
Conflicts
No configured conflict was identified.
Effective doses
1 of 1 assessed ingredients meet the saved minimum amount threshold.
Study evidence

Ingredients

IngredientAmount per servingScore
Calcium (Dicalcium Phosphate)
40 mg
Vinpocetine
10 mg 92
Adults 18–50 Women
Report overview
A Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyB+ Value
Each serving provides 10 mg of vinpocetine, with the amount recorded separately. At the serving price, 10 mg corresponds to about $0.14 of the whole product.
How this ingredient is rated

Active Ingredient Quality & Bioavailability91

Vinpocetine is identified and its amount is recorded; the evaluation recognizes ordinary excipients.
Vinpocetine Identity and Source
Vinpocetine is identified with an amount of 10 mg per serving.
Excipient and Filler Quality
The evaluation recognizes ordinary excipients; that alone does not characterize the entire ingredient list.

Dose, Safety & Label Transparency100

Each serving contains 10 mg of vinpocetine, with its individual amount recorded.
Vinpocetine Dosage Alignment
The recorded vinpocetine amount is 10 mg per serving.
Proprietary Blend Disclosure
The vinpocetine amount is recorded separately, so it can be identified without estimating a blend share.

Value80

The whole-product serving costs about $0.14; the price comparison reflects the vinpocetine amount.
Cost Efficiency per 10mg Dose
At the serving price, 10 mg of vinpocetine corresponds to about $0.14 of the whole product.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Combination of Vinpocetine and Dexamethasone Alleviates Cognitive Impairment in Nasopharyngeal Carcinoma Patients following Radiation Injury.
    Zhang P; Cao Y; Chen S; Shao L · Pharmacology · 2021
    Randomized trial60 participantsBrain Health forVinpocetine
  2. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study.
    Szilágyi G; Nagy Z; Balkay L; Boros I; Emri M; Lehel S; Márián T; Molnár T; Szakáll S; Trón L; Bereczki D; Csiba L; Fekete I; Kerényi L; Galuska L; Varga J; Bönöczk P; Vas A; Gulyás B · Journal of the neurological sciences · 2005
    Randomized trial13 participantsBrain Health forVinpocetine
  3. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine.
    Bönöczk P; Gulyás B; Adam-Vizi V; Nemes A; Kárpáti E; Kiss B; Kapás M; Szántay C; Koncz I; Zelles T; Vas A · Brain research bulletin · 2001
    Narrative reviewBrain Health forVinpocetine
  4. Effect of vinpocetine (cognitolâ„¢) on cognitive performances of a nigerian population.
    Ogunrin A · Annals of medical and health sciences research · 2014
    Non-randomized trial112 participantsBrain Health Mental Focus forVinpocetine
  5. [Study of the effects of vinpocetin on cognitive functions].
    Valikovics A; Csányi A; Németh L · Ideggyogyaszati szemle · 2012
    Clinical trialBrain Health forVinpocetine
  6. "Brain-specific" nutrients: a memory cure?
    McDaniel MA; Maier SF; Einstein GO · Nutrition (Burbank, Los Angeles County, Calif.) · 2004
    Narrative reviewMental Focus forVinpocetine
  7. Psychopharmacological effects of vinpocetine in normal healthy volunteers.
    Subhan Z; Hindmarch I · European journal of clinical pharmacology · 1985
    Randomized trial12 participantsMental Focus forVinpocetine